Cell Transplantation, Vol. 24, pp. 879–890, 2015 Printed in the USA. All rights reserved. Copyright © 2015 Cognizant Comm. Corp.

0963-6897/15 $90.00 + .00 DOI: http://dx.doi.org/10.3727/096368913X676899 E-ISSN 1555-3892 www.cognizantcommunication.com

Two Distinct Mechanisms Mediate the Involvement of Bone Marrow Cells in Islet Remodeling: Neogenesis of Insulin-Producing Cells and Support of Islet Recovery Svetlana Iskovich,* Nitza Goldenberg-Cohen,† Tamila Sadikov,*† Isaac Yaniv,‡ Jerry Stein,§ and Nadir Askenasy* *Frankel Laboratory, Schneider Children’s Medical Center of Israel, Petach Tikva, Israel †Krieger Eye Research Laboratory, Center for Stem Cell Research, Schneider Children’s Medical Center of Israel, Petach Tikva, Israel ‡Department of Pediatric Hematology-Oncology, Schneider Children’s Medical Center of Israel, Petach Tikva, Israel §Bone Marrow Transplant Unit, Schneider Children’s Medical Center of Israel, Petach Tikva, Israel

We have recently reported that small-sized bone marrow cells (BMCs) isolated by counterflow centrifugal elutriation and depleted of lineage markers (Fr25lin−) have the capacity to differentiate and contribute to regeneration of injured islets. In this study, we assess some of the characteristics of these cells compared to elutriated hematopoietic progenitors (R/O) and whole BMCs in a murine model of streptozotocin-induced chemical diabetes. The GFPbrightCD45+ progeny of whole BMCs and R/O progenitors progressively infiltrate the pancreas with evolution of donor chimerism; are found at islet perimeter, vascular, and ductal walls; and have a modest impact on islet recovery from injury. In contrast, Fr25lin− cells incorporate in the islets, convert to GFPdimCD45−PDX-1+ phenotypes, produce proinsulin, and secrete insulin with significant contribution to stabilization of glucose homeostasis. The elutriated Fr25lin− cells express low levels of CD45 and are negative for SCA-1 and c-kit, as removal of cells expressing these markers did not impair conversion to produce insulin. BMCs mediate two synergistic mechanisms that contribute to islet recovery from injury: support of islet remodeling by hematopoietic cells and neogenesis of insulin-producing cells from stem cells. Key words: Chemical diabetes; Islet remodeling; b-Cell regeneration; Insulin-producing cells; Bone marrow stem cells; Hematopoietic progenitors; Bone marrow transplantation


recipients, as also observed after UCB cell grafting in neonate immunodeficient mice (69). Insulin production has been detected in particular subsets of stem cells after islet injury (36,46): very small embryonic-like (VSEL) cells corresponding to a cluster of differentiation 45-negative stem cell antigen 1 (lymphocyte antigen 6 complex, locus A; Ly6a)-positive chemokine C-X-C motif receptor 4-positive lineage-negative (CD45−SCA-1+CXCR4+lin−) phenotype (22,55) and small-sized elutriated cells (elutriated flow rate 25 ml/min; Fr25) devoid of lineage markers (Fr25lin−) (24). Altogether these data suggest that neogenesis of insulin-producing cells is a rather low-efficiency mechanism of islet repair, provided that the autoimmune reaction is controlled or abrogated (26). On the other hand, most studies have shown beneficial effects of cellular and cytokine interventions on islet remodeling and recovery from injury without significant conversion to produce insulin (8,12,19,33,39,40,42,45,66,68).

Hematopoietic stem and progenitor cells (HSPCs) derived from various sources have been considered as candidates for regeneration of the endocrine pancreas in type 1 diabetes. Intense work dedicated to islet regeneration suggests two major approaches to substitution of the injured tissue and restoration of insulin production: neogenesis from stem cells and support of endogenous recovery. A proof of concept for neogenesis is the successful induction of insulin production in a variety of cells in vitro, including bone marrow-derived mesenchymal stromal cells (MSCs) (35,48), adherent and nonadherent bone marrow and blood fractions (49,65), and umbilical cord blood (UCB) cells (9,13,62). However, in vivo conversion of cells derived from hematopoietic compartments remains controversial (13). On the one hand, murine cells derived from the bone marrow (23) and spleen (36) and human UCB cells (21) incorporate in the islets of irradiated

Received June 12, 2013; final acceptance December 18, 2013. Online prepub date: December 30, 2013. Address correspondence to Nadir Askenasy, M.D., Ph.D., Frankel Laboratory, Center for Stem Cell Research, Schneider Children’s Medical Center of Israel, 14 Kaplan Street, Petach Tikva, Israel 49202. Tel: +972 3921 3954; Fax: +972 3921 4156; E-mail: [email protected]



Hematopoietic cells play a general supportive role for endogenous islet recovery through activation of pancreatic progenitors, expansion of b-cells, and conversion of a-cells (11,44,66,70). These supportive activities have been attributed to MSCs, immune cells, hematopoietic, and endothelial progenitors derived from the bone marrow and UCB (12,13), which generally came short of restoring glycemic control (1,6,7,18,27,39,41,47,56). The first mechanism involves direct and indirect support of revascularization and neovascularization, which has been demonstrated for whole bone marrow cells (BMCs) (8,19,39,64), adherent BMC subsets (39,40,45), lineagenegative (lin−) (19,47), and c-kit+lin− progenitors (19). The second mechanism involves local immunomodulation attained by MSCs (7,33,40,42), and one or multiple BMC infusions (6,19). Combined vascular and immunogenic activities have been also achieved by bone marrow activation with 5-fluorouracil (8), mobilization (64), and cotransplantation (43). The third mechanism is support of islet stroma, which is an additional mechanism of MSC activity (7,40), and local provision of growth factors such as hepatocyte growth factor and insulin-like growth factor-1 (1,12,27,42). We have used a subset of small-sized BMCs isolated by counterflow centrifugal elutriation (Fr25lin−) to demonstrate significant incorporation in chemically injured islets (24). These stem cells convert to express markers specific of hepatocytes, epithelia, and glia in vitro and in vivo (15,16,28,37) in addition to durable multilineage hematopoietic reconstitution (30,31). Another fraction isolated by elutriation contains primarily large-sized progenitors in various stages of differentiation, endowed with radioprotective activity due to short-term reconstituting capacity (30,31). This study aims to resolve some of the controversies regarding the role of bone marrow-derived cells in islet recovery. We focused on the involvement of various subsets in two major mechanisms of islet recovery from injury: neogenesis of insulin-producing cells and support of islet remodeling. We found that these mechanisms are mediated by distinct bone marrow subsets including small-sized stem cells and large-sized progenitors, without apparent possibility of prospective identification using putative HSPC markers. MATERIALS AND METHODS Animal Preparation, Diabetes, and Transplantation Mice used in this study were C57Bl/6J (B6, H2Kb, protein tyrosine phosphatase, receptor type Cb; CD45.2), B6.SJL-Ptprca Pepcb/BoyJ (H2Kb, protein tyrosine phosphatase, receptor type Ca peptidase Cb; CD45.1), and C57BL/6-TgN(ACTbEGFP)1Osb [enhanced green fluorescent protein (GFP) under the control of a chicken b-actin promoter and cytomegalovirus enhancer, H2kb, CD45.2]; they were purchased from Jackson Laboratories (Bar Harbor,


ME, USA) and housed in a barrier facility. The Institutional Animal Care Committee of the Schneider Medical Center approved all procedures (#022B6229 dated 4/1/ 2009). Diabetes was induced in female mice (aged 6–8 weeks) by five daily consecutive intraperitoneal injections of 60 mg/g streptozotocin (STZ; Calbiochem, Darmstadt, Germany). Blood glucose levels were monitored with a standard glucometer (Accu-Chek Sensor; Roche Diagnostics, Basel, Switzerland) in mice fed ad libitum at constant daytime hours (9–11 AM). Diabetes was considered at glucose levels exceeding 250 mg/dl in two consecutive measurements. Before cell transplantation (day 0), recipients were sublethally irradiated at 675 rad (total body irradiation) using an X-ray irradiator (RadSource 2000, Suwanee, GA, USA) at a rate of 106 rad/min (day −1). For transplantation, cells suspended in 0.2 ml phosphatebuffered saline (Sigma-Aldrich, St. Louis, MO, USA) were infused into the lateral tail vein. Cell Isolation Whole BMCs (wBMCs) from wild-type or GFPpositive male donors (aged 6–8 weeks) were harvested by flushing of medullar cavities of femur, tibia, and iliac bones. Single cell suspensions (5 × 108 cells) were loaded into the chamber of a counterflow centrifuge (Beckman Instruments, Palo Alto, CA, USA) operating at a constant speed of 3,000 rpm (1,268 × g). Fractions were collected in 200 ml at an elutriation flow rate of 25 ml/min to isolate the smallest subset of nucleated cells (Fr25), and the largest cells were collected in the rotor off position (R/O). Fr25 cells were lineage-depleted by incubation with saturating amounts of rat anti-mouse monoclonal antibodies (mAb) against CD5 (clone 53–7.3, T-cells), B220 (clone RA3-3A1/6.1, B-lymphocytes), GR-1 (clone RB6-8C5, granulocytes), Mac-1 (clone M1/70, macrophages), extracted from hybridoma cell lines (ATCC, Manassas, VA, USA) and purified TER119 (erythroid; eBioscience, San Diego, CA, USA). Antibody-bound cells were incubated with goat anti-rat secondary antibodies conjugated to magnetic beads at a ratio of four to five beads per cell (Dynal Biotech, Oslo, Norway) and were collected by exposure to a magnetic field. Flow Cytometry Measurements were performed with a Vantage SE flow cytometer (Becton Dickinson, Franklin Lakes, NJ, USA) on cells that underwent red cell lysis (34). Hematopoietic chimerism was determined by GFP fluorescence or mAb against minor antigens CD45.1 (clone A20; eBioscience) and CD45.2 (clone 104; eBioscience) and the antibodies mentioned above. Data were acquired using several combinations of fluorochromes, including fluorescein-isothyocyanate (FITC), phycoerythrin (PE), allophycocyanin (APC), and peridinin chlorophyll protein complex (PerCP) (all from BD


Pharmingen). In all measurements, nonspecific binding was prevented by addition of 1 ml mouse serum. Determination of Blood Insulin Serum from mice was collected by centrifugation and assessed in 96-well microtiter assay plates (Millipore, Billerica, MA, USA) using the rat/mouse insulin enzymelinked immunosorbent assay (ELISA) kit (R&D Systems, Abingdon, UK). Absorbance at 450 nm and 590 nm was determined using an ELISA PowerWave-10 in a plate reader (BioTeK, Winooski, VT, USA). Insulin standards were used to determine a calibration curve. Tissue Preparation Mice were sacrificed by CO2 asphyxiation, and infusion of ice-cold fixative containing 1.5% fresh paraformaldehyde and 0.1% glutaraldehyde (Sigma-Aldrich) was performed with a miniperistaltic pump (P720; Instech, Plymouth Meeting, PA, USA) through a blunt 20-gauge needle (Victorg, Kanpur, India) placed in the left ventricle. Excised pancreata were placed in this medium for 2 h at 4°C for additional fixation, immersed in 30% sucrose overnight (Sigma-Aldrich), embedded in optimal cutting temperature media (Sakura Finetek, Torrance, CA, USA), and frozen in isopentane (Sigma-Aldrich) suspended in liquid nitrogen. Tissue was sectioned (3–6 mm) with a cryotome (Thermo Shandon, Runcorn, Cheshire, UK). Immunofluorescence and FISH Immunofluorescence was designed according to several considerations to allow detection of the donor cells with variable GFP fluorescence intensities (25). Nuclei were labeled with Hoechst-33342 (1:1,000; Molecular Probes, Eugene, OR, USA), and sections were mounted in antifade medium (Dako, Glostrup, Denmark). Serial cryosections were immunostained with primary antibodies for 1 h and counterstained with respective secondary antibodies for 30 min at room temperature: polyclonal mouseanti-proinsulin (1:20; R&D Systems), goat-anti-pancreatic and duodenal homeobox 1 (PDX-1; 1:5,000, kindly provided by Shimon Efrat), biotinylated anti-mouse CD45 (1:100; Biolegend, San Diego, CA), and biotinylated rabbitanti-GFP (1:100; Santa Cruz Biotechnology, Santa Cruz, CA, USA). These primary antibodies were counterstained with FITC-labeled donkey anti-rabbit (1:200; Jackson Immunoresearch, West Grove, PA, USA) and goat antirat mAb (1:200; Santa Cruz), Alexa Flour 568-conjugated donkey anti-goat (1:500), and cyanine 3 (Cy3)-conjugated rat anti-goat (1:200; Molecular Probes). Biotinylated primary antibodies were counterstained with Cy3-conjugated streptavidin (1:400) and Cy5-conjugated streptavidin (1:500) purchased from Jackson Immunoresearch. The Y chromosome in male donor cells was visualized in fresh sections or immunostained slides after treatment


with 0.025% pepsin (Invitrogen, Grand Island, NY, USA) for 30 min at 37°C (25). Nuclear probes (Applied Spectral Imaging, Migdal Haemek, Israel) were denatured, and probe hybridization was performed overnight, followed by sequential wash in 0.4× saline sodium citrate buffer (SSC; Sigma-Aldrich) and 2× SSC stringency solution supplemented with 0.1% NP4O detergent (Sigma-Aldrich). Slides were washed and mounted with antifade containing 4¢,6-diamidino-2-phenylindole (DAPI; Sigma-Aldrich). Images were acquired with an Axioplan 2 (C. Zeiss, Göttingen, Germany) fluorescence microscope equipped with an Apotome using AxioVision 4.5 and LSM 510 software, respectively. Images were pseudocolored and RGB reconstructed using Adobe Photoshop software (San Francisco, CA, USA). Real-Time PCR and Western Blots Western blot for PDX-1 used rabbit anti-PDX-1 polyclonal antibodies (1:500; Chemicon, Billerica, MA, USA) and peroxidase-conjugate goat anti-rabbit IgG (1:10,000; Jackson Immunoresearch). RT-qPCR was used to study the expressions of CD45, c-kit, and Sca-1. Elutriated fractions were frozen in liquid nitrogen, total RNA was extracted with TRIzol (Invitrogen), followed by reverse transcription into cDNA using random hexamers (Amersham Biosciences, Cardiff, UK), and Moloney murine leukemia virus reverse transcriptase (Promega, Madison, WI, USA). cDNA was analyzed with a Sequence Detection System (ABI Prism 7900; Applied Biosystems, Foster City, CA, USA). Gene expression was measured by normalization of cDNA input levels against mouse b-actin. Reactions were performed for forward and reverse primers in Master Mix buffer (SYBR Green I; Applied Biosystems) according to the PCR cycling conditions previously described (4,16). Standard curves were obtained using untreated mouse cDNA for each gene PCR assay and quantified by the comparative Ct method (4,15). Primers used for analysis are delineated in Table 1. Statistical Analysis Data are presented as means ± standard deviations for each experimental protocol. Results in each experimental group were evaluated for reproducibility by linear regression of duplicate measurements. Differences between the experimental protocols were estimated with a post hoc Scheffe t-test, and significance was considered at p < 0.05. RESULTS Cellular Composition and Hematopoietic Function of Elutriated Subsets Counterflow centrifugal elutriation selects subsets of BMCs according to density: small-sized cells (Fr25) and large-sized progenitors collected in the R/O position, each one of the subsets accounting for ~20% of the sample



Table 1. Primers

b-Actin Insulin Pdx-1 CD45 c-kit Sca-1





Pdx-1, pancreatic and duodenal homeobox 1; CD45, cluster of differentiation 45; Sca-1, stem cell antigen-1.

(30,31,53). These cell populations differ substantially in contents of the various lineages (Fig. 1), with myelomonocytic progenitors predominantly found in the R/O subset (Fig. 1B) and erythroid and lymphoid cells in the Fr25 subset (Fig. 1A). Depletion of the various lineages from the Fr25 subset results in an enriched population of small-sized stem cells (Fr25lin−) displaying variable CD45 expression (Fig. 1C). These subsets have distinct hematopoietic activities: R/O cells mediate short-term reconstitution, while Fr25lin− cells are devoid of radioprotective activity, and their slow activation mediates long-term durable multilineage reconstitution (30,31). Therefore, we

validated our elutriation technique in a competitive engraftment assay; both subsets were grafted into lethally irradiated syngeneic hosts with constitutive expression of GFP (Fig. 1D). At 3 weeks posttransplantation (short term), the donor hematopoietic progeny was predominantly of R/O cell origin (CD45.2+GFP−), whereas at 16 weeks posttransplant (long term), donor chimerism originated primarily from the Fr25lin− subset (CD45.1+GFP−). The differential radioprotective activities of these subsets isolated by elutriation were also evident from the significant mortality of mice grafted with Fr25lin− cells alone and survival of all recipients of R/O progenitors (Table 2A).

Figure 1. Composition and characteristics of elutriated BMC subsets. (A) Fractional composition of hematopoietic lineages within the elutriated rotor off (R/O; n = 5) and flow rate of 25 ml/min (Fr25; n = 13) subsets: T-cells (CD5), B lymphocytes (B220), granulocytes (GR-1), macrophages (Mac-1), erythroid (Ter-119), and lineage-negative cells (lin −). (B) Demonstrative plots of GR-1 expression in the R/O and Fr25lin− subsets. (C) Analysis of cell size, hematopoietic lineage markers, and CD45 in wBMCs (n = 28), R/O progenitors (n = 9), and the Fr25 subset before (n = 38) and after depletion of lineage-positive cells (Fr25lin−, n = 21). (D) Irradiated (850 rad) GFP+ recipients were grafted with 5 × 105 minor antigen disparate Fr25lin− cells (GFP− CD45.1) and 5 × 105 R/O cells (GFP− CD45.2). Chimerism was determined by gating on GFP− cells after 3 and 16 weeks for identification of the progeny of the two subsets. PE, phycoerythrin; APC, allophycocyanin.



Table 2. Consequences of Cellular Transplants A. Short Term (3 Weeks)

STZ + 675 rad wBMC R/O Fr25lin− R/O + Fr25lin−


Mortality (%)

Chimerism 3 Weeks

29 9 19 34 8

16 (43) 0 0 7 (16) 0

— 79 ± 9 89 ± 6 16 ± 3 85 ± 7

p Value Versus wBMCs

Peak Blood Glucose (mg/dl)

p Value Versus STZ

0.05 0.001 NS

480 ± 70 500 ± 70 390 ± 85 330 ± 80 240 ± 53

NS 0.05 0.005 0.001

B. Long Term (16 Weeks)

STZ + 675 rad wBMC R/O Fr25lin− R/O + Fr25lin−


Blood Glucose (mg/dl) 16 Weeks

p Value Versus STZ

Insulin (ng/ml)

p Value Versus STZ

13 9 19 27 8

415 ± 82 345 ± 59 285 ± 65 205 ± 48 190 ± 35

NS 0.005 0.001 0.001

0.43 ± 0.09 0.53 ± 0.12 0.55 ± 0.2 0.84 ± 0.2 0.93 ± 0.4

NS NS 0.001 0.005

wBMC, whole bone marrow cell; STZ, streptozotocin; R/O, rotor off; Fr25lin−, elutriated fraction 25 lineage-negative cells; NS, not significant.

Differential Effects of Cell Subsets on Recovery From Chemical Diabetes To evaluate the impact of transplantation of various cell subsets on the course of chemical diabetes, we used sublethal irradiation, attempting to shed light on the mechanisms of BMC transplantation on islet recovery from injury. This established model (8,14,19,22,24,25,40,64,68) includes selective injury by five consecutive doses of 60 mg/g STZ (days −6 to −2) followed by sublethal irradiation (675 rad) and cell grafting after 1 day (Fig. 2A). Under these conditions, the mice develop severe hyperglycemia (Fig. 2B) with significant mortality (Table 2A), both parameters being effectively ameliorated by cotransplantation of Fr25lin− cells and R/O progenitors. Histological analysis of the islets revealed incorporation of GFPdim cells in the inner sections of the islets and the presence of GFPbright cells at the islet perimeter (Fig. 2C). To dissociate between the contributions of the two subsets, they were individually grafted into diabetic mice. Male Fr25lin− cells, identified by a genomic marker, produced proinsulin, incorporated in the inner regions of the islets (Fig. 2D), expressed PDX-1 (Fig. 2E), and mediated a significant reduction in blood glucose levels (Table 2A). Notably, reduced blood glucose levels in recipients of Fr25lin− cells alone and in conjunction with R/O progenitors are attributed to the corresponding increase in insulin levels at 16 weeks posttransplant (Table 2B). In variance, transplantation of R/O progenitors and whole bone marrow cells had little impact on glucose homeostasis (Fig. 3A) and insulin levels (Table 2B) despite early

evolution of donor chimerism (Table 2A). Donor R/O progenitors localized to the islet perimeter, particularly adjacent to the vascular pedicle, and retained bright GFP intensity and were negative for PDX-1 staining (Fig. 3B). Similar qualitative analysis after transplantation of wBMCs showed significant numbers of GFPbright donor cells surrounding the islets, ducts, and pancreatic vasculature (Fig. 3C). These cells were largely negative for proinsulin (Fig. 3C), and the vast majority expressed the pan-hematopoietic marker CD45 (Fig. 3D), corroborating the absence of significant conversion to adopt endocrine phenotypes and produce insulin. These findings recapitulate prior reports of incorporation in injured pancreata of grafted wBMCs and hematopoietic progenitors (6–8,11,14,19,39,40,46,47,64,66,70). Fr25lin− cells are in fact a minor subset of BMCs, questioning whether the numbers of stem cells within the wBMC grafts were too low for detection of conversion. To evaluate this possibility, sublethally irradiated mice with chemical diabetes were grafted with 3 × 107 BMCs, which contain an equivalent of 106 Fr25lin− cells (~20% Fr25 cells of which ~15% are collected after lineage depletion). The outcome of these transplants was not different from the long-term outcome of mice grafted with 5 × 106 BMCs (Table 2B), indicating that the low Fr25lin− numbers were not responsible for the poor outcome of wBMC transplants. Hematopoietic Progenitor Markers Do Not Delineate Islet-Engrafting Cells Controversial evidence on neogenesis of insulinproducing cells has been presented by studies using



Figure 2. Incorporation and functional conversion of Fr25lin− cells. (A) Experimental design: chemical diabetes was induced by five consecutive doses of 60 mg/g STZ, sublethal irradiation at 675 rad, and syngeneic cell transplantation in C57/Bl6 mice. (B) Blood glucose levels of sublethally irradiated diabetic mice (STZ, n = 13) and after cotransplantation of 106 R/O progenitors and 106 Fr25lin− cells (n = 8). (C) Histological analysis of islets (identified by proinsulin staining) of recipients of Fr25lin − and R/O cells discloses GFPdim cells incorporated in the inner islet areas (yellow arrows) and GFP bright cells surrounding the islets (white arrows) juxtaposed to ducts and venules (scale bar: 20 mm). (D) Positive identification of male cells (Y chromosome, encircled) incorporated in the inner islet regions of a female recipient, coexpressing pancreatic and duodenal homeobox 1 (PDX-1) and proinsulin (scale bar: 10 mm). (E) Demonstrative confocal images of coexpression of nuclear PDX-1 and cytosolic GFP after transplantation of Fr25lin− cells in diabetic mice (scale bar: 5 mm). DAPI, 4¢,6-diamidino-2-phenylindole (nuclear stain).

hematopoietic progenitor markers such as SCA-1 and ckit, ranging from positive identification of differentiation (22,46) to negative results (19,68). The positive identification of Fr25lin− cell conversion to produce insulin (24) was used to address the possible use of these markers for prospective identification of the candidate stem cells that participate in islet regeneration. As shown in prior studies (59), Sca-1 and c-kit are variably expressed in the Fr25 subset, and lineage depletion

results in further decrease in cell surface expression of these markers and CD45 (Fig. 4A). Considering that progenitor commitment and priming might be detectable only at the transcriptional level (50), mRNA encoding these markers was assessed in the small-sized cells. Elutriation of Fr25 cells and lineage depletion corresponded to decreased levels of mRNA encoding c-kit and Sca-1 (Fig. 4B), showing that progenitors expressing these markers are not enriched by the elutriation procedure. In



Figure 3. Consequences of transplantation of whole BMCs and progenitors. (A) Blood glucose levels in mice with chemical diabetes after transplantation of 5 × 106 syngeneic whole BMCs (n = 9) and 106 R/O progenitors (n = 19). (B) Grafted R/O progenitors surrounding the injured islets (white arrows) express bright GFP and do not stain for proinsulin (scale bar: 40 mm). (C, D) GFPbright cells within the vasculature and surrounding the ducts detected after transplantation of whole BMCs. These cells do not express the transcription factor PDX-1 (C, scale bar: 20 mm) and express the panhematopoietic marker CD45 (D, scale bar: 40 mm).

the next stage, we sought to assess the possible participation of progenitors demarcated by these markers in islet regeneration by their depletion from the Fr25lin− subset. Transplantation of SCA-depleted and kitdepleted cells had no significant impact on recovery from chemical diabetes mediated by the Fr25lin− cells (Fig. 4C), indicating that these hematopoietic markers are

neither obligatory nor characteristic of bone marrowderived cells that convert to adopt endocrine phenotypes. DISCUSSION Transplantation of murine BMCs augments islet recovery from chemical injury through two main mechanisms. The major mechanism is neogenesis of insulin-producing



Figure 4. Characterization of hematopoietic progenitor markers in Fr25lin − cells and their contribution to islet recovery from injury. (A) Expression of CD45, c-kit, and stem cell antigen 1 (SCA-1) on the surface of freshly elutriated Fr25 and lineagedepleted (Fr25lin−) cells. Data are normalized against expression in wBMCs (n = 5). (B) Measurements of c-kit and SCA-1 expression in the corresponding subsets as determined by flow cytometry. (C) Transcriptional profiles of CD45, c-kit, and SCA-1 in Fr25 and Fr25lin− cells as determined by real-time PCR. Data are normalized against mRNA contents in wBMCs (n = 3). (D) Blood glucose levels after day 100 in sublethally irradiated diabetic mice (STZ + rad, n = 13) and after transplantation of 106 Fr25lin− cells (n = 27), and equal number of the Fr25lin− subset depleted of c-kit (n = 10) and SCA-1 (n = 10). PerCp, peridinin chlorophyll protein complex.

cells from small-sized stem cells within the bone marrow. The minor mechanism is indirect support of islet remodeling by hematopoietic progenitors that generate early hematopoietic chimerism, along with activities of mesenchymal cells and endothelial progenitors (7,12,13,40,47). Because autologous hematopoietic transplants do not abrogate autoimmunity indefinitely (3,34) due to excessive conditioning (2), MSCs might offer an alternative to immunogenic control of the autoimmune disorder (12,33) in particular derived from UCB (13). Our data emphasize several distinct activities of smallsized stem cells and large-sized progenitors in a model of toxic injury to the pancreatic islets. First, competitive engraftment assays showed early reconstitution from R/O progenitors endowed with radioprotective activity and delayed functional reconstitution from small-sized Fr25lin− cells, which become the predominant source of durable mulilineage hematopoiesis (30). Therefore, consistent with sequential engraftment of various bone marrow-derived progenitors (31,38,53), elutriation dissociates functionally distinct subsets of stem cells and progenitors. Second, the patterns of cell incorporation in the injured islets disclose

differential affinities to central and peripheral regions of the injured islets, which also correlate with the intensity of GFP expression. Fr25lin− cells engraft primarily in the inner regions of the islets and downregulate GFP expression, as a feature of active differentiation (24,25). In variance, hematopoietic progenitors and their progeny are found in the vasculature, ductal walls, and at islet perimeter, sustaining bright GFP signals. The activities of these cells are largely supportive of islet remodeling, including neovascularization (8,19,39,44,47,64), immunomodulation (6,7,12,39,42), stabilization of the stroma (7,40), and provision of cytokines (1,27). Third, the therapeutic efficacy of the two subsets attributes clear advantage of the Fr25lin− cells in stabilization of glucose levels through sustained increase in insulin levels. In contrast, R/O progenitors and whole BMC grafts share limited capacity to elevate insulin levels, corroborating the partial and transient reduction in blood glucose levels mediated by hematopoietic progenitors (6,7,14,18,27,39,41,47,56). Small-sized nucleated BMCs differentiate into various nonhematopoietic lineages in vivo, expressing markers specific of hepatocytes, astrocytes, endothelium, retinal


neurons, and endocrine pancreas in response to selective injury (15,16,24,28). The most convincing evidence of such differentiation is the evolution of multiple epithelial cell types following transplantation of single Fr25lin− cells, which also demonstrates the self-renewal capacity of these primitive precursors in vivo (37). The characteristics of differentiating Fr25lin− cells in the injured islets include upregulation of PDX-1, downregulation of tacking markers such as GFP, production of proinsulin, and secretion of insulin. Since Fr25lin− cells represent a small fraction of nucleated BMCs, the numbers of candidate stem cells might be insufficient in wBMC grafts used for hematopoietic reconstitution (6–8,14,19,22,39, 40,47). However, transplantation of large BMC numbers, containing equivalent fractions of the elutriated Fr25lin− subset, resulted in undetectable morphological and functional incorporation in the islets. It is therefore the way these cells are prepared for transplantation rather than their numbers that determine their capacity to convert and produce insulin. Possibly, extraction of Fr25lin− cells by elutriation exposes them to stress that terminates their dormant state and primes them to differentiation. The smallsized elutriated cells are mitotically quiescent in the host bone marrow (38), have no radioprotective activity under limiting dilution conditions (60), and initiate indefinite multilineage hematopoiesis after several weeks (28,29,53). In fact, epithelial and hepatic differentiation within days (28,37) and endocrine, glial, and neural differentiation within weeks (15,16,24) precede in time the engagement of these cells in long-term hematopoietic reconstitution. The plausible explanation is that these residents of a dedicated hematopoietic compartment such as the bone marrow require stronger inhibitions of hematopoietic differentiation in order to preserve a pool of long-term reconstituting HSPCs. This may be the cause of their slow initiation and delayed hematopoietic activity. The two distinct mechanisms of BMC support of islet regeneration and remodeling question the differentiation capacity of hematopoietic progenitors positively identified by cell surface markers. R/O progenitors, wBMCs, and their progeny sustained bright GFP signals and were located at the islet perimeter, the vascular pedicles, and surrounding the ducts, similar to the location reported for progenitors expressing c-kit and SCA-1 (19,46,68). Exclusion of Fr25lin− cells expressing either one of these progenitor markers had no significant impact on endocrine differentiation, thus they cannot be used for prospective identification of candidate stem cells (8,19,39,64). In addition, the early activity of c-kit and SCA-1 signaling is dispensable in neogenesis of insulin-producing cells, without excluding the possibility of their upregulation and activation in later stages of differentiation. Our findings are consistent with the contention that the most primitive precursors residing in the bone marrow (29) express neither SCA-1


nor c-kit (10,52). These markers are expressed by committed hematopoietic progenitors responsible for both shortand long-term reconstitution (51,61,67), but are not essential or characteristic of long-term repopulating cells (59). In fact, c-kit and SCA-1 are neither unique nor specific to hematopoietic differentiation and are often expressed in pancreatic (17,57), endodermal (20), hepatic (20,54,58) and neural progenitors (67), and MSCs (5,63). Analysis of CD45 expression reinforced the contention that endocrine differentiation is restricted to the most primitive progenitors (stem cells) within the bone marrow. This pan-hematopoietic marker was detectable in GFPbright cells surrounding the islets (19,39,40,47), but not in insulinproducing cells derived from the Fr25lin− cells (24), CD45−SCA-1+CXCR4+lin− (VSEL) (22,55), and splenocytes (36). Although the Fr25lin− subset shares with VSEL cells the small size, absence of lineage markers and CD45−/low expression, Fr25lin− cells converting to produce insulin are largely characterized by a SCA-1 negative phenotype. The competitive nature of engraftment may be one of the restrictions of the limited capacity of distinct subsets of hematopoietic precursors to convert into insulin-producing cells. Expression of progenitor markers defines a certain degree of commitment, and their primary activity in irradiated hosts is hematopoietic reconstitution. We observed that total body irradiation is rather detrimental to quantitative incorporation of Fr25lin− cells in the ischemic retina (4), due to the high affinity of these cells to the bone marrow (32,38). It is undetermined yet whether the grafted Fr25lin− cells migrate directly to sites of injury or are primed in the bone marrow and are trapped in the aplastic marrow space of irradiated hosts. The current data emphasize two distinct mechanisms of adult bone marrow-derived cell participation in islet recovery from chemical injury. Hematopoietic cells, MSCs, and endothelial progenitors mediate immune, vascular, stromal, and cytokine-mediated mechanisms of support of islet remodeling after injury with modest impact on glucose homeostasis (1,6–8,14,18,19,22,27,39,40,46,47,56,64). A major contribution to glycemic control is conferred by neogenesis of insulin-producing cells from primitive precursors residing in the adult bone marrow, which can be isolated by counterflow elutriation. These regenerative cells do not express lineage and hematopoietic progenitor markers, display variable CD45, silence GFP, express PDX-1, produce proinsulin, convert, and secrete insulin. The beneficial effects of multiple cell types with distinct mechanisms on islet remodeling and regeneration are promising toward development of cell-based therapeutic approaches to type 1 diabetes. ACKNOWLEDGMENTS: We thank Dr. Saul Sharkis and Dr. Michael Collector for the outstanding support, discussion, and conceptual contribution to this study. Funding was provided



by a generous grant from the Leah and Edward M. Frankel Trust for bone marrow transplantation and the Zanvyl and Isabelle Krieger Fund, Israel Academy of Sciences and Humanities (1371/08), the Eldor-Metzner Clinician Scientist Award, Chief Scientist, Israel Ministry of Health (3-3741), and a Pilot Grant from North American Neuro-Ophthalmology Society. Author contributions: Performance of experiments: S.I., N.G., T.S., N.A. Collection of data: S.I., N.G., T.S., I.Y., J.S. Analysis and interpretation: N.G., I.Y. Manuscript writing: J.S., N.A. Conception and design: N.A. The authors declare no conflicts of interest.

REFERENCES 1. Agudo, J.; Ayuso, E.; Jimenez, V.; Salavert, A.; Casellas, A.; Tafuro, S.; Haurigot, V.; Ruberte, J.; Segovia, J. C.; Bueren, J.; Bosch, F. IGF-I mediates regeneration of endocrine pancreas by increasing beta cell replication through cell cycle protein modulation in mice. Diabetologia 51: 1862–1872; 2008. 2. Askenasy, E. M.; Askenasy, N.; Askenasy, J. J. Does lymphopenia preclude restoration of immune homeostasis? The particular case of type 1 diabetes. Autoimmun. Rev. 9: 687–690; 2010. 3. Askenasy, N. Hematopoietic transplants for disease suppression and cure in type 1 diabetes. Curr. Stem Cell Res. Ther. 8:333–339; 2013. 4. Avraham-Lubin, B. C.; Goldenberg-Cohen, N.; Sadikov, T.; Askenasy, N. VEGF induces neuroglial differentiation in bone marrow-derived stem cells and promotes microglia conversion following mobilization with GM-CSF. Stem Cell Rev. 8:1199–1210; 2012. 5. Baddoo, M.; Hill, K.; Wilkinson, R.; Gaupp, D.; Hughes, C.; Kopen, G. C.; Phinney, D. G. Characterization of mesenchymal stem cells isolated from murine bone marrow by negative selection. J. Cell. Biochem. 89:1235–1249; 2003. 6. Banerjee, M.; Kumar, A.; Bhonde, R. R. Reversal of experimental diabetes by multiple bone marrow transplantation. Biochem. Biophys. Res. Commun. 328:318–325; 2005. 7. Boumaza, I.; Srinivasan, S.; Witt, W. T.; Feghali-Bostwick, C.; Dai, Y.; Garcia-Ocana, A.; Feili-Hariri, M. Autologous bone marrow-derived rat mesenchymal stem cells promote PDX-1 and insulin expression in the islets, alter T cell cytokine pattern and preserve regulatory T cells in the periphery and induce sustained normoglycemia. J. Autoimmun. 32: 33–42; 2009. 8. Choi, J. B.; Uchino, H.; Azuma, K.; Iwashita, N.; Tanaka, Y.; Mochizuki, H.; Migita, M.; Shimada, T.; Kawamori, R.; Watada, H. Little evidence of transdifferentiation of bone marrow-derived cells into pancreatic beta cells. Diabetologia 46:1366–1374; 2003. 9. Denner, L.; Bodenburg, Y.; Zhao, J. G.; Howe, M.; Cappo, J.; Tilton, R. G.; Copland, J. A.; Forraz, N.; McGuckin, C.; Urban, R. Directed engineering of umbilical cord blood stem cells to produce C-peptide and insulin. Cell Prolif. 40: 367–380; 2007. 10. Doi, H.; Inaba, M.; Yamamoto, Y.; Taketani, S.; Mori, S. I.; Sugihara, A.; Ogata, H.; Toki, J.; Hisha, H.; Inaba, K.; Sogo, S.; Adachi, M.; Matsuda, T.; Good, R. A.; Ikehara, S. Pluripotent hemopoietic stem cells are c-kit
12. Fiorina, P.; Voltarelli, J.; Zavazava, N. Immunological applications of stem cells in type 1 diabetes. Endocr. Rev. 32: 725–754; 2011. 13. Francese, R.; Fiorina, P. Immunological and regenerative properties of cord blood stem cells. Clin. Immunol. 136: 309–322; 2010. 14. Gao, X.; Song, L.; Shen, K.; Wang, H.; Niu, W.; Qin, X. Transplantation of bone marrow derived cells promotes pancreatic islet repair in diabetic mice. Biochem. Biophys. Res. Commun. 371:132–137; 2008. 15. Goldenberg-Cohen, N.; Avraham-Lubin, B. C.; Sadikov, T.; Goldstein, R. S.; Askenasy, N. Primitive stem cells derived from bone marrow express glial and neuronal markers and support revascularization in injured retina exposed to ischemic and mechanical damage. Stem Cells Dev. 21:1488– 1500; 2012. 16. Goldenberg-Cohen, N.; Avraham-Lubin, B. C.; Sadikov, T.; Askenasy, N. Effect of co-administration of neuronal growth factors on neuroglial differentiation of bone marrow-derived stem cells in the ischemic retina. Invest. Ophthalmol. Vis. Sci. 55(1):502–512; 2014. 17. Gong, J.; Zhang, G.; Tian, F.; Wang, Y. Islet-derived stem cells from adult rats participate in the repair of islet damage. J. Mol. Histol. 43:745–750; 2012. 18. Hasegawa, Y.; Ogihara, T.; Yamada, T.; Ishigaki, Y.; Imai, J.; Uno, K.; Gao, J.; Kaneko, K.; Ishihara, H.; Sasano, H.; Nakauchi, H.; Oka, Y.; Katagiri, H. Bone marrow (BM) transplantation promotes beta-cell regeneration after acute injury through BM cell mobilization. Endocrinology 148: 2006–2015; 2007. 19. Hess, D.; Li, L.; Martin, M.; Sakano, S.; Hill, D.; Strutt, B.; Thyssen, S.; Gray, D. A.; Bhatia, M. Bone marrow-derived stem cells initiate pancreatic regeneration. Nat. Biotechnol. 21:763–770; 2003. 20. Hisatomi, Y.; Okumura, K.; Nakamura, K.; Matsumoto, S.; Satoh, A.; Nagano, K.; Yamamoto, T.; Endo, F. Flow cytometric isolation of endodermal progenitors from mouse salivary gland differentiate into hepatic and pancreatic lineages. Hepatology 39:667–675; 2004. 21. Huang, C. J.; Butler, A. E.; Moran, A.; Howe, M.; Cappo, J.; Tilton, R. G.; Copland, J. A.; Forraz, N.; McGuckin, C.; Urban, R. A low frequency of pancreatic islet insulinexpressing cells derived from cord blood stem cell allografts in humans. Diabetologia 54:1066–1074; 2011. 22. Huang, Y.; Kucia, M.; Hussain, L. R.; Wen, Y.; Xu, H.; Yan, J.; Ratajczak, M. Z.; Ildstad, S. T. Bone marrow transplantation temporarily improves pancreatic function in streptozotocininduced diabetes: Potential involvement of very small embryonic-like cells. Transplantation 89:677–685; 2010. 23. Ianus, A.; Holz, G. G.; Theise, N. D.; Hussain, M. A. In vivo derivation of glucose-competent pancreatic endocrine cells from bone marrow without evidence of cell fusion. J. Clin. Invest. 111:843–850; 2003. 24. Iskovich, S.; Goldenberg-Cohen, N.; Stein, J.; Yaniv, I.; Fabian, I.; Askenasy, N. Elutriated stem cells derived from the adult bone marrow differentiate into insulin-producing cells in vivo and reverse chemical diabetes. Stem Cells Dev. 21:86–96; 2012. 25. Iskovich, S.; Goldenberg-Cohen, N.; Stein, J.; Yaniv, I.; Farkas, D. L.; Askenasy, N. b-Cell neogenesis: Experimental considerations in adult stem cell differentiation. Stem Cells Dev. 20:569–582; 2011. 26. Iskovich, S.; Kaminitz, A.; Pearl-Yafe, M.; Stein, J.; Yaniv, I.; Askenasy, N. Participation of adult bone marrow-derived



28. 29. 30. 31.

32. 33.









stem cells in pancreatic regeneration: Neogenesis versus endogenesis. Curr. Stem Cell Res. Ther. 2:272–279; 2007. Izumida, Y.; Aoki, T.; Yasuda, D.; Koizumi, T.; Suganuma, C.; Saito, K.; Murai, N.; Shimizu, Y.; Hayashi, K.; Odaira, M.; Kusano, T.; Kushima, M.; Kudano, M. Hepatocyte growth factor is constitutively produced by donor-derived bone marrow cells and promotes regeneration of pancreatic b-cells. Biochem. Biophys. Res. Commun. 333:273–282; 2005. Jang, Y. Y.; Collector, M. I.; Baylin, S. B.; Diehl, A. M.; Sharkis, S. J. Hematopoietic stem cells convert into liver cells within days without fusion. Nat. Cell Biol. 6:532–539; 2004. Jang, Y. Y.; Sharkis, S. J. Stem cell plasticity: A rare cell, not a rare event. Stem Cell Rev. 1:45–51; 2005. Jones, R. J.; Celano, P.; Sharkis, S. J.; Sensenbrenner, L. L. Two phases of engraftment established by serial bone marrow transplantation in mice. Blood 73:397–401; 1989. Jones, R. J.; Collector, M. I.; Barber, J. P.; Vala, M. S.; Fackler, M. J.; May, W. S.; Griffin, C. A.; Hawkins, A. L.; Zehnbauer, B. A.; Hilton, J. Colvin, O. M.; Sharkis, S. J. Characterization of mouse lymphohematopoietic stem cells lacking spleen colony-forming activity. Blood 88:487–491; 1996. Juopperi, T. A.; Sharkis, S. J. Isolation of quiescent murine hematopoietic stem cells by homing properties. Methods Mol. Biol. 430:21–30; 2008. Jurewicz, M.; Yang, S.; Augello, A.; Godwin, J. G.; Moore, R. F.; Azzi, J.; Fiorina, P.; Atkinson, M.; Sayegh, M. H.; Abdi, R. Congenic mesenchymal stem cell therapy reverses hyperglycemia in experimental type 1 diabetes. Diabetes 59: 3139–3147; 2010. Kaminitz, A.; Mizrahi, K.; Yaniv, I.; Farkas, D. L.; Stein, J.; Askenasy, N. Low levels of allogeneic but not syngeneic hematopoietic chimerism reverse autoimmune insulitis in prediabetic NOD mice. J. Autoimmun. 33:83–91; 2009. Karnieli, O.; Izhar-Prato, Y.; Bulvik, S.; Efrat, S. Generation of insulin-producing cells from human bone marrow mesenchymal stem cells by genetic manipulation. Stem Cells 25:2837–2844; 2007. Kodama, S.; Kuhtreiber, W.; Fujimura, S.; Dale, E. A.; Faustman, D. L. Islet regeneration during the reversal of autoimmune diabetes in NOD mice. Science 302:1223– 1227; 2003. Krause, D. S.; Theise, N. D.; Collector, M. I.; Henegariu, O.; Hwang, S.; Gardner, R.; Neutzel, S.; Sharkis, S. J. Multi-organ, multi-lineage engraftment by a single bone marrow-derived stem cell. Cell 105:369–377; 2001. Lanzkron, S. M.; Collector, M. I.; Sharkis, S. J. Hematopoietic stem cell tracking in vivo: A comparison of short-term and long-term repopulating cells. Blood 93:1916–1921; 1999. Lechner, A.; Yang, Y. G.; Blacken, R. A.; Wang, L.; Nolan, A. L.; Habener, J. F. No evidence for significant transdifferentiation of bone marrow into pancreatic beta-cells in vivo. Diabetes 53:616–623; 2004. Lee, R. H.; Seo, M. J.; Reger, R. L.; Spees, J. L.; Pulin, A. A.; Olson, S. D.; Prockop, D. J. Multipotent stromal cells from human marrow home to and promote repair of pancreatic islets and renal glomeruli in diabetic NOD/scid mice. Proc. Natl. Acad. Sci. USA 103:17438–17443; 2006. Li, F. X.; Zhu, J. W.; Tessem, J. S.; Varella-Garcia, M.; Jensen, J.; Hogan, C. J.; DeGregori, J. The development of diabetes in E2f1/E2f2 mutant mice reveals important roles for bone marrow-derived cells in preventing islet cell loss. Proc. Natl. Acad. Sci. USA 100:12935–13940; 2003.


42. Luo, J. Z.; Xiong, F.; Al-Homsi, A. S.; Ricordi, C.; Luo, L. Allogeneic bone marrow cocultured with human islets significantly improves islet survival and function in vivo. Transplantation 95:801–809; 2013. 43. Luo, J. Z.; Xiong, F.; Al-Homsi, A. S.; Roy, T.; Luo, L. G. Human BM stem cells initiate angiogenesis in human islets in vitro. Bone Marrow Transplant. 46:1128–1137; 2011. 44. Luo, L. Islet transplantation challenge - Human islet longevity: A potential solution from bone marrow cells. J. Bioanal. Biomed. 4:e107; 2012. 45. Luo, L.; Badiavas, E.; Luo, J. Z.; Maizel, A. Allogeneic bone marrow supports human islet beta cell survival and function over six months. Biochem. Biophys. Res. Commun. 361:859–864; 2007. 46. Luo, L.; Luo, L. Z.; Xiong, F.; Abedi, M.; Greer, D. Cytokines inducing bone marrow SCA+ cells migration into pancreatic islet and conversion into insulin-positive cells in vivo. PLoS One 4:e4504; 2009. 47. Mathews, V.; Hanson, P. T.; Ford, E.; Fujita, J.; Polonsky, K. S.; Graubert, T. A. Recruitment of bone marrow-derived endothelial cells to sites of pancreatic beta-cell injury. Diabetes 53:91–98; 2004. 48. Moriscot, C.; de Fraipont, F.; Richard, M. J.; Marchand, M.; Savatier, P.; Bosco, D.; Favrot, M.; Benhamou, P. Y. Human bone marrow mesenchymal stem cells can express insulin and key transcription factors of the endocrine pancreas developmental pathway upon genetic and/or microenvironmental manipulation in vitro. Stem Cells 23:594–603; 2005. 49. Oh, S. H.; Muzzonigro, T. M.; Bae, S. H.; LaPlante, J. M.; Hatch, H. M.; Petersen, B. E. Adult bone marrow-derived cells trans-differentiating into insulin-producing cells for the treatment of type I diabetes. Lab. Invest. 84:607–617; 2004. 50. Orkin, S. H.; Zon, L. I. Hematopoiesis and stem cells: Plasticity versus developmental heterogeneity. Nat. Immunol. 3: 323–328; 2002. 51. Orlic, D.; Fischer, R.; Nishikawa, S.; Nienhuis, A. W.; Bodine, D. M. Purification and characterization of heterogeneous pluripotent hematopoietic stem cell populations expressing high levels of c-kit receptor. Blood 82:762–770; 1993. 52. Ortiz, M.; Wine, J. W.; Lohrey, N.; Ruscetti, F. W.; Spence, S. E.; Keller, J. R. Functional characterization of a novel hematopoietic stem cell and its place in the c-Kit maturation pathway in bone marrow cell development. Immunity 10:173–182; 1999. 53. Pearl-Yafe, M.; Stein, J.; Yolcu, E. S.; Farkas, D. L.; Shirwan, H.; Yaniv, I.; Askenasy, N. Fas transduces dual apoptotic and trophic signals in hematopoietic progenitors. Stem Cells 25:3194–3203; 2007. 54. Petersen, B. E.; Goff, J. P.; Greenberger, J. S.; Michalopoulos, G. K. Hepatic oval cells express the hematopoietic stem cell marker Thy-1 in the rat. Hepatology 27:433–445; 1998. 55. Ratajczak, M. Z.; Zuba-Surma, E.; Wojakowski, W.; Suszynska, M.; Mierzejewska, K.; Liu, R.; Ratajczak, J.; Shin, D. M.; Kucia, M. Very small embryonic-like stem cells (VSELs) represent a real challenge in stem cell biology: Recent pros and cons in the midst of a lively debate. Leukemia 28:473–484; 2014. 56. Rosengren, A. H.; Taneera, J.; Rymo, S.; Renström, E. Bone marrow transplantation stimulates pancreatic b-cell replication after tissue damage. Islets 1:10–18; 2009. 57. Rovira, M.; Scott, S. G.; Liss, A. S.; Jensen, J.; Thayer, S. P.; Leach, S. D. Isolation and characterization of centroacinar/ terminal ductal progenitor cells in adult mouse pancreas. Proc. Natl. Acad. Sci. USA 107:75–80; 2010.


58. Seaberg, R. M.; Smukler, S. R.; Kieffer, T. J.; Enikolopov, G.; Asghar, Z.; Wheeler, M. B.; Korbutt, G.; van der Kooy, D. Clonal identification of multipotent precursors from adult mouse pancreas that generate neural and pancreatic lineages. Nat. Biotechnol. 22:1115–1124; 2004. 59. Sharkis, S. J.; Collector, M. I.; Barber, J. P.; Vala, M. S.; Jones, R. J. Phenotypic and functional characterization of the hematopoietic stem cell. Stem Cells 15(Suppl 1):41–45; 1997. 60. Sharkis, S. J.; Neutzel, S.; Collector, M. I. Phenotype and function of hematopoietic stem cells. Ann. NY Acad. Sci. 938:191–195; 2001. 61. Spangrude, G. J.; Heimfeld, S.; Weissman, I. L. Purification and characterization of mouse hematopoietic stem cells. Science 241:58–62; 1998. 62. Sun, B.; Roh, K. H.; Lee, S. R.; Lee, Y. S.; Kang, K. S. Induction of human umbilical cord blood-derived stem cells with embryonic stem cell phenotypes into insulin producing islet-like structure. Biochem. Biophys. Res. Commun. 354: 919–923; 2007. 63. Sun, S.; Guo, Z.; Xiao, X.; Liu, B.; Liu, X.; Tang, P. H.; Mao, N. Isolation of mouse marrow mesenchymal progenitors by a novel and reliable method. Stem Cells 21: 527–535; 2003. 64. Taneera, J.; Rosengren, A.; Renstrom, E.; Nygren, J. M.; Serup, P.; Rorsman, P.; Jacobsen, S. E. Failure of transplanted bone marrow cells to adopt a pancreatic beta-cell fate. Diabetes 55:290–296; 2006.


65. Tang, D. Q.; Cao, L. Z.; Burkhardt, B. R.; Xia, C. Q.; Litherland, S. A.; Atkinson, M. A.; Yang, L. J. In vivo and in vitro characterization of insulin-producing cells obtained from murine bone marrow. Diabetes 53:1721–1732; 2005. 66. Thorel, F.; Népote, V.; Avril, I.; Kohno, K.; Desgraz, R.; Chera, S.; Herrera, P. L. Conversion of adult pancreatic alpha-cells to beta-cells after extreme beta-cell loss. Nature 464:1149–1154; 2010. 67. Uchida, N.; Jerabek, L.; Weissman, I. L. Searching for hematopoietic stem cells. II. The heterogeneity of Thy-1.1 (lo)Lin(-/lo)Sca-1+ mouse hematopoietic stem cells separated by counterflow centrifugal elutriation. Exp. Hematol. 24:649–659; 1996. 68. Wagers, A. J.; Sherwood, R. I.; Christensen, J. L.; Weissman, I. L. Little evidence for developmental plasticity of adult hematopoietic stem cells. Science 297:2256–2259; 2002. 69. Yoshida, S.; Ishikawa, F.; Kawano, N.; Shimoda, K.; Nagafuchi, S.; Shimoda, S.; Yasukawa, M.; Kanemaru, T.; Ishibashi, H.; Shultz, L. D.; Harada, M. Human cord blood-derived cells generate insulin-producing cells in vivo. Stem Cells 23:1409–1416; 2005. 70. Zorina, T. D.; Subbotin, V. M.; Bertera, S.; Alexander, A. M.; Haluszczak, C.; Gambrell, B.; Bottino, R.; Styche, A. J.; Trucco, M. Recovery of the endogenous beta cell function in the NOD model of autoimmune diabetes. Stem Cells 21: 377–388; 2003.


Two distinct mechanisms mediate the involvement of bone marrow cells in islet remodeling: neogenesis of insulin-producing cells and support of islet recovery.

Cell Transplantation, Vol. 24, pp. 879–890, 2015 Printed in the USA. All rights reserved. Copyright © 2015 Cognizant Comm. Corp. 0963-6897/15 $90.00 ...

866KB Sizes 0 Downloads 0 Views

Recommend Documents

The co-transplantation of bone marrow derived mesenchymal stem cells reduced inflammation in intramuscular islet transplantation.
Although the muscle is one of the preferable transplant sites in islet transplantation, its transplant efficacy is poor. Here we attempted to determine whether an intramuscular co-transplantation of mesenchymal stem cells (MSCs) could improve the out

Transdifferentiation of Bone Marrow Mesenchymal Stem Cells into the Islet-Like Cells: the Role of Extracellular Matrix Proteins.
Pancreatic islet implantation has been recently shown to be an efficient method of treatment for type 1 diabetes. However, limited availability of donor islets reduces its use. Bone morrow would provide potentially unlimited source of stem cells for

Human Fallopian tube as a novel source of multipotent stem cells with potential for islet neogenesis.
Presence of stem cells in the female genital tract has been reported; however stem cell status of Fallopian tube remains unexplored. In the present study, we show for the first timean existence of stem cells in a Fallopian tube. A pure population of

Snf chromatin remodeling complexes modulates Pdx1 activity in islet β cells.
Pdx1 is a transcription factor of fundamental importance to pancreas formation and adult islet β cell function. However, little is known about the positive- and negative-acting coregulators recruited to mediate transcriptional control. Here, we isola

In vitro differentiation of human adipose tissue-derived stem cells into islet-like clusters promoted by islet neogenesis-associated protein pentadecapeptide.
Human adipose tissue-derived stem cells (hASCs) are considered an ideal tool for the supply of insulin-producing cells to treat diabetes mellitus, with high differentiation efficiency. Islet neogenesis-associated protein (INGAP) is an initiator of is

Involvement of bone marrow cells and neuroinflammation in hypertension.
Microglial activation in autonomic brain regions is a hallmark of neuroinflammation in neurogenic hypertension. Despite evidence that an impaired sympathetic nerve activity supplying the bone marrow (BM) increases inflammatory cells and decreases ang

Regenerating islet-derived protein 1 inhibits the activation of islet stellate cells isolated from diabetic mice.
Emerging evidence indicates that the islet fibrosis is attributable to activation of islet stellate cells (ISCs). In the present study, we compared the differences in biological activity of ISCs isolated from diabetic db/db and non-diabetic db/m mice

Survival of free and encapsulated human and rat islet xenografts transplanted into the mouse bone marrow.
Bone marrow was recently proposed as an alternative and potentially immune-privileged site for pancreatic islet transplantation. The aim of the present study was to assess the survival and rejection mechanisms of free and encapsulated xenogeneic isle

Isolation and characterization of islet stellate cells in rat.
The central role of PSCs in pancreatic fibrogenesis is well established. However, the mechanism responsible for the islet fibrosis presenting in the late stage of T2DM has not been fully elucidated. This study was designed to determine whether the en

Islet α cells and glucagon--critical regulators of energy homeostasis.
Glucagon is secreted from islet α cells and controls blood levels of glucose in the fasting state. Impaired glucagon secretion predisposes some patients with type 1 diabetes mellitus (T1DM) to hypoglycaemia; whereas hyperglycaemia in patients with T1